15 Female Founders Share What Inspired Them To Begin
Insights With TrendHunter CEO, Jeremy Gutsche
AI and AR Research Tackling Real-World Problems says Facebook’s Director of Research
Innovation is Keeping the Balance Between Creativity but Staying Practical
The Initial Spark Of Creativity Is More Important Than Intelligence
Creativity And Innovation Starts With Trust & Freedom
Planning Corporate Sustainability Programs: Eight Leaders on Where to Start
8 Experts On The Top Corporate Sustainability Issue Right Now
The Ever-Evolving Role of the Chief Sustainability Officer
Dr. Martin Akerman is the Co-founder and CTO of Envisagenics.
He is the inventor of the SpliceCore software platform, born out of his extensive research experience at the intersection of biology and data science and his vision of discovering RNA therapeutics using machine learning. Martin trained as a post doctorate fellow with Dr. Adrian Krainer from Cold Spring Harbor Laboratory, where he helped in the development of Spinraza®, the first FDA-approved RNA therapeutic for treating Spinal Muscular Atrophy. He received his PhD in Bioinformatics from Technion, Israel Institute of Technology in 2009. As a first-time entrepreneur, Martin represented Envisagenics in winning the J&J AI for Drug Discovery QuickFire challenge in 2017 and Microsoft’s Innovate.AI challenge in 2018. His goal is to combine cutting-edge computation with RNA domain expertise to develop innovative drugs for cancer and neurodegeneration.
Sign up to our newsletter for updates on live events in your area, new content and interviews